ASLAN Pharmaceuticals announced positive interim results from the Phase 2 study of eblasakimab in moderate-to-severe atopic dermatitis (AD) adult patients previously treated with dupilumab, TREK-DX. The primary endpoint, which is the percent change in Eczema Area Severity Index (EASI) score from baseline to week 16, was statistically significant when compared to placebo (p=0.0059), even though the interim analysis was not powered for statistical significance due to the sample size. ASLAN announced positive results from the Phase 2b TREK-AD study of eblasakIMab in moderate-to- severe biologic-naive AD patients in July 2023, and is currently investigating eblasakimab In dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4437 USD | +1.98% | +7.96% | -15.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.02% | 10.04M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.65% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ASLN Stock
- News ASLAN Pharmaceuticals Limited
- ASLAN Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients